Insulin Regular, Human
Brand name: Afrezza
Rank #137 of 500 drugs by total cost
$119.4M
Total Cost
143,017
Total Claims
$119.4M
Total Cost
6,122
Prescribers
$835
Cost per Claim
11,248
Beneficiaries
204,345
30-Day Fills
$19K
Avg Cost/Provider
23
Avg Claims/Provider
About Insulin Regular, Human
Insulin Regular, Human (sold as Afrezza) was prescribed 143,017 times by 6,122 Medicare Part D providers in 2023, costing the program $119.4M. At $835 per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 134 | Olaparib (Lynparza) | $121.1M | 8,744 |
| 135 | Empagliflozin/Metformin Hcl (Synjardy Xr) | $119.7M | 121,366 |
| 136 | Edaravone (Radicava Ors) | $119.6M | 8,588 |
| 137 | Insulin Regular, Human (Afrezza) | $119.4M | 143,017 |
| 138 | Ezetimibe (Ezetimibe) | $118.1M | 2,859,001 |
| 139 | Ambrisentan (Ambrisentan) | $117.7M | 23,927 |
| 140 | Memantine Hcl (Memantine Hcl) | $117.5M | 2,268,098 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology